How Long Oral Semaglutide Stays in Your System — and Why It Matters

What the MHRA approval data says about how semaglutide accumulates in your body

The MHRA's approval of the Wegovy tablet in June 2026 drew on phase-3 clinical evidence showing that once-daily oral semaglutide, co-formulated with the absorption enhancer SNAC, achieves meaningful plasma concentrations despite the gut's usual barriers to protein absorption. Semaglutide's half-life (around seven days) is consistent across both the injected and tablet forms. That extended half-life means the medicine does not work in neat daily pulses. Instead, each tablet adds to a gradually rising pool of circulating semaglutide until a steady state is reached, typically after four to five weeks of unbroken daily dosing.

This is why the dosing schedule starts low and escalates slowly: 1.5 mg for the first month, then 4 mg, then 9 mg, up to 25 mg maintenance. Starting at 25 mg from day one would mean crossing through the same accumulation curve far more abruptly, with predictably worse nausea. The patient information published by the MHRA on the MHRA's Yellow Card scheme page and via the eMC reinforces this: the dose ladder is there to let your system adjust, not to test your willpower.

One practical consequence: if you miss a day, semaglutide's long presence in your bloodstream provides more buffering than a shorter-acting medicine would. That does not make missed doses irrelevant, consistent daily dosing is what sustains the steady-state concentration that drives appetite reduction. But a single missed tablet is unlikely to reset weeks of accumulation.

How the one-week half-life shapes what happens when you stop

A medicine with a seven-day half-life takes roughly five half-lives to reduce to below 3% of its peak concentration. In practice that means oral semaglutide clears your system over approximately four to five weeks after your final tablet. Appetite tends to return during that window, often gradually rather than all at once, as plasma levels fall through the range where the drug's receptor activity is meaningful.

This clearance timeline matters in several clinical contexts. The NHS England guidance on weight-management injections (which applies to the injectable and, by extension, the pharmacological class) recommends telling your surgical and anaesthetic team that you are taking a GLP-1 medicine before any planned procedure. Delayed gastric emptying persists while semaglutide remains in your system, which is relevant to anaesthetic risk. Your prescriber will advise on any pre-operative pause.

For anyone considering pregnancy, the picture is also shaped by that five-week clearance window. These medicines are not recommended during pregnancy or breastfeeding, and a wash-out period before trying to conceive is advised. The MHRA and NHS guidance are clear on this; the Wegovy tablet overview explains the context in more detail. Specific timing should always be agreed with your prescriber.

Why the absorption mechanism of the tablet changes the duration story slightly

The Wegovy tablet relies on SNAC to temporarily raise the local pH in the stomach wall and allow semaglutide to cross into the bloodstream. This is a finely tuned process: the tablet must be swallowed whole, first thing in the morning, with no more than a small sip of plain water, and you need to wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. Fat, coffee, and other tablets all disrupt SNAC's absorption window.

Because bioavailability via the oral route is lower and more variable than via injection, the clinical results seen in the OASIS 4 trial (around 13.6% average weight loss over 64 weeks compared with roughly 2.4% on placebo, with adherent participants achieving closer to 17%) were reached using higher absolute doses than the injected form requires. The 25 mg maintenance tablet delivers a comparable active effect to the 2.4 mg weekly injection in terms of systemic semaglutide exposure. How these results compare in practice is worth reading alongside this page if you are weighing up the tablet against the injection.

No refrigeration is needed for the tablet, which removes one of the practical frictions of the injectable form. Worth knowing: for people considering treatment, if you are ready to buy semaglutide tablets through a registered pharmacy, the tablet arrives in plain, unbranded packaging with DPD tracking, so there is nothing in the delivery to signal what is inside.

What steady state means for when you feel results, and when clearance begins

Steady-state concentration is reached when the daily dose being added equals the amount leaving your system each day. With a seven-day half-life, that equilibrium typically lands around week four or five at any given dose. This is why the timeline for noticing changes on the Wegovy tablet is measured in weeks, not days. Appetite reduction tends to build as plasma levels climb rather than arriving in a distinct moment.

After stopping, the reverse applies. Clearance is not a cliff, it mirrors the gradual build, with levels falling week by week. For most people, the bulk of the pharmacological effect is gone within three to four weeks, and the medicine is effectively cleared by week five. Weight regain in clinical trials following discontinuation of GLP-1 medicines has been documented, which is why continuing treatment (and the clinical review that accompanies each repeat order) matters.

These questions are exactly the kind our prescribers field regularly. If you are thinking about which weight-loss treatment fits your situation, a clinical review is the right place to start. There is no algorithm involved: a GPhC-registered prescriber reads your consultation and responds the same day.

If you have more general questions about the process, our FAQs cover many of the common ones. And when you are ready to discuss your own circumstances, you can speak to our prescribers through a free consultation.